US 12,465,658 B2
Eye drop composition
Nesva Goris, Leawood, KS (US); Johan Neyts, Leawood, KS (US); Erwin Blomsma, Leawood, KS (US); Stefaan Wera, Leawood, KS (US); Ainola Billiet, Leawood, KS (US); Joeri Auwerx, Leawood, KS (US); Veerle Debeurme, Leawood, KS (US); Maryline Roe, Leawood, KS (US); and Pascal Puig, Leawood, KS (US)
Assigned to Aratana Therapeutics, Inc., Leawood, KS (US)
Filed by Aratana Therapeutics, Inc., Leawood, KS (US)
Filed on Jan. 5, 2024, as Appl. No. 18/405,670.
Application 18/405,670 is a division of application No. 17/205,673, filed on Mar. 18, 2021, granted, now 11,904,024.
Application 17/205,673 is a continuation of application No. 14/828,365, filed on Aug. 17, 2015, granted, now 10,967,074, issued on Apr. 6, 2021.
Application 14/828,365 is a continuation of application No. 14/373,322, granted, now 9,107,943, issued on Aug. 18, 2015, previously published as PCT/EP2012/050843, filed on Jan. 20, 2012.
Prior Publication US 2024/0148909 A1, May 9, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 49/00 (2006.01); A61K 9/00 (2006.01); A61K 31/305 (2006.01); A61K 31/522 (2006.01); A61K 47/24 (2006.01); A61K 47/40 (2006.01)
CPC A61K 49/0004 (2013.01) [A61K 9/0048 (2013.01); A61K 31/305 (2013.01); A61K 31/522 (2013.01); A61K 47/24 (2013.01); A61K 47/40 (2013.01)] 20 Claims
 
1. A composition comprising:
at least 0.1% w/v 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1, 9-dihydro-6H-Purin-6-one; and
at least 10-99% w/v of a cyclodextrin.